Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Lilly 3Q

Lilly's revenues grew 7% in 3Q09 to $5.6 billion

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lilly 3Q09

3Q Revenues: $5.6 billion (+7%)

3Q Earnings: $942 million (loss of $466 million in 3Q08)

YTD Revenues: $15.9 billion (+5%)

YTD Earnings: $3.4 billion (+119%)

Comments: Earnings comparisons were affected by Lilly’s 3Q08 charge of $1.5 billion to settle federal and state investigations into Zyprexa marketing practices. U.S. revenues rose 14% to $3.1 billion, while ex-U.S. figures fell 1% to $2.4 billion. In 3Q09, Zyprexa revenues rose 3% to $1.2 billion, Cymbalta rose 10% to $790 million, Humalog rose 16% to $500 million, and Almita sales grew 47% to $462 million. For the YTD, Zyprexa is flat at $3.5 billion, Cymalta is up 14% to $2.2 billion, Humalog is up 12% to $1.4 billion and Alimta is up 41% to $1.2 billion. Beseiged by generic competition, Gemzar sales fell 25% to $332 million in 3Q09 and 19% to $1.1 billion YTD. The company recognized sales and collaboration revenues of $102 million for Erbitux, which it acquired when it bought ImClone.

Read our Lilly profile in this year’s Top Companies Report!

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters